Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013)

Trial Profile

Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013)

Completed
Phase of Trial: Phase 0

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Roflumilast (Primary) ; Prednisone
  • Indications Haematological malignancies
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Aug 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 07 Apr 2015 Planned End Date changed from 1 Jul 2015 to 1 Jul 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top